Coronavirus | Eli Lilly India combination gets nod for emergency use
Eli Lilly and Company India on Tuesday mentioned it has obtained permission for emergency use of its antibody medication combination used for therapy of gentle to average COVID-19.
The firm has obtained permission for restricted emergency use of its monoclonal antibody medication, bamlanivimab 700 mg and etesevimab 1400 mg, used collectively for the therapy, it mentioned in a press release.
“Lilly is engaging in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab to speed up access and provide treatment options for patients with COVID-19.” The combination has been authorised beneath Emergency Use Authorisation within the U.S. and choose E.U. nations, the assertion mentioned.
“We are pleased that we have another innovative treatment option to offer India’s healthcare providers who continue to be at the forefront of the battle against COVID-19,” firm India MD Luca Visini mentioned.
Earlier in May, Eli Lilly had additionally obtained permission for the emergency use of baricitinib in combination with remdesivir, for the therapy of suspected or laboratory confirmed COVID-19 in India, the assertion mentioned.